Nuclear Medicine Europe

Nuclear Medicine Europe attended "The Economist World Cancer Series Europe 2026" in Brussels on 8-9 June, bringing together policymakers, clinicians, patient advocates and #industry leaders to discuss the future of #cancercare in Europe. We have prepared a dedicated report analysing the discussions through the lens of #nuclearmedicine : what the key debates mean for the sector, for patient access, and for the broader policy environment in which our industry operates. The conclusions are clear: nuclear medicine is no longer a peripheral topic in European cancer policy. Read our full report below. https://lnkd.in/dwDisfi4 #isotopes #radioisotopes #radiopharmaceuticals #healthcare

It's been a very busy week! Nuclear Medicine Europe held its Annual General Assembly in Brussels this Wednesday, followed by Security of Supply and Therapy Working Groups meetings on Thursday, bringing together more than 60 representatives from across the #nuclearmedicine industry. This year's assembly welcomed several new members to the association: Agilera Pharma AS, Perspective Therapeutics, Boston Scientific, ETSA Global Logistics, S.A.U., S.M.E. , NUCLIDIUM AG, and Demcon life sciences & health. Each brings expertise, perspectives and energy to our working groups and advocacy activities. The AGM session included presentations from our partners at Euratom Supply Agency and European Association of Nuclear Medicine (EANM), updates on the US-EU tariffs situation, reports from each Working Group Chair on their respective activities, and the traditional networking opportunities across these three days. As always, we thank all participants for their engagement and contributions. The Nuclear Medicine Europe Winter Connects, will take place at the end of November, with several Working Group physical meetings scheduled, but we will be present in the industry hall of the EANM Annual Congress in Vienna this October. We wish all our members, partners and friends a wonderful summer. #Radiopharmaceuticals #NMEU #isotopes #radioisotopes #healthcare

Nuclear Medicine Europe attended the Friends of Europe "Reimagining Europe's Health Systems" summit, where policymakers, industry leaders and health system experts gathered to debate the future of European healthcare. The central message was clear: health is no longer a cost centre but a strategic asset, on par with energy, defence and digital infrastructure. Our reporting from the summit focuses on what these discussions mean for #nuclearmedicine specifically. Read our long-form reporting "How the debates on Europe's future health systems align with nuclear medicine priorities and perspectives". Don't hesitate to let us know if you would like this type of reporting and coverage more frequently.

Press release : Nuclear Medicine Europe is pleased to announce two new Working Group Chair appointments, reflecting the association's ongoing commitment to advancing #nuclearmedicine policy and supply security across Europe. Marjolijn Droog-Kuiper MBA has been elected Chair of the Security of Supply Working Group. With over a decade of experience in medical isotopes at NRG PALLAS, including her current role as Executive Director Medical Isotope Solutions, Marjolijn brings deep expertise in supply chain management and isotope production at one of the world's leading medical isotope facilities. Lada Georgieva, PhD has been elected Co-chair of the Therapy Working Group. Currently Director of Policy and Public Affairs for Region Europe at Novartis, Lada brings extensive experience in healthcare policy, strategic partnerships, and advancing patient access to innovative therapies including radioligand therapy. We warmly welcome both Marjolijn and Lada in their new roles, and look forward to the expertise and leadership they will bring to their respective working groups at a critical time for the sector. The full press release is available in the news section of our website : https://lnkd.in/dVXNReQZ #pressrelease #RadioligandTherapy #radioisotopes #Radiopharmaceuticals

This week marks #EuropeanWeekAgainstCancer, addressing critical challenges in cancer care across Europe. Access to innovative cancer treatments remains uneven across Member States. For #nuclearmedicine, this means patients in some countries can access #radioligand therapies months or years before others, despite identical clinical needs. Nuclear Medicine Europe Members and Working Groups are working to address these disparities through: • Developing next-generation therapeutic #radiopharmaceuticals • Supporting clinical trial infrastructure across European centers • Advocating for regulatory harmonization that speeds patient access without compromising safety. Equitable access isn't just a policy goal, it's about ensuring every European cancer patient can benefit from precision treatments when they need them most. This week's focus areas - early detection, access to medicines, patients and survivors, and research - reflect the core of nuclear medicine's contribution to cancer care. Nuclear Medicine Europe fully supports this initiative and invites you to learn more about Europe's ongoing efforts to improve cancer outcomes: https://lnkd.in/dbbVJDUT

Four Europeans are diagnosed with cancer every minute. Addressing this challenge requires sustained focus on therapeutic innovation. The European Medicines Agency has now published a Horizon Scanning Report specifically focused on #radiopharmaceuticals. Excellent news for the industry and a significant recognition of therapeutic #nuclearmedicine's role in cancer care. As the voice of the European nuclear medicine industry, Nuclear Medicine Europe has maintained ongoing dialogue with EMA through our working groups, contributing to consultations and regulatory discussions on radiopharmaceuticals and therapeutic applications. EMA's dedicated focus on this sector - which will propose recommendations to shape future regulatory frameworks - is recognition of the field's importance and potential. We look forward to continuing our role in ensuring #industry expertise informs the development of frameworks that enable innovation while ensuring patient access to these life-saving therapies. See EMA's recommendations for the future of radiopharmaceuticals in Europe:  https://lnkd.in/d76hG38z

Following European #policy discussions that directly or indirectly affect the #nuclearmedicine industry is a complex and time-consuming task. The Nuclear Medicine Europe EU Health Policy Watch monitors, compiles, and synthesizes ongoing developments at the EU level to deliver a clear, efficient digest that is both informative and relevant. It remains the most effective way to stay informed on what's happening in the EU policy sphere. The latest edition is now available to Nuclear Medicine Europe members. This month's issue covers the European Commission's €330 million investment in nuclear technologies with a significant focus on medical isotopes, the Cyprus Presidency's proposal for a European Centre of Clinical Excellence for Pharmaceuticals, concerns over medicine supply security amid Middle East tensions, and calls from Medicines for Europe to strengthen the Critical Medicines Act. Research updates include new findings on rising cancer rates in Europe and improvements in cancer care efficiency. Access the latest issue in the member area : https://lnkd.in/dajxHmr3